頸動脈狭窄治療法の世界市場:抗血栓薬、抗高脂血症薬、降圧薬

LINEで送る

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Antithrombotics – Market size and forecast 2018-2023

Antihyperlipidemics – Market size and forecast 2018-2023

Antihypertensives – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Entry of generic drugs

Technological advances in medical devices

Increasing demand for curative therapies

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Amgen Inc.

AstraZeneca Plc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co.

Eli Lilly and Co.

F. Hoffmann-La Roche Ltd.

Johnson & Johnson Services Inc.

Merck & Co., Inc.

Pfizer Inc.

Sanofi

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Product – Market share 2018-2023 (%)

Exhibit 19: Comparison by product

Exhibit 20: Antithrombotics – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Antithrombotics – Year-over-year growth 2019-2023 (%)

Exhibit 22: Antihyperlipidemics – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Antihyperlipidemics – Year-over-year growth 2019-2023 (%)

Exhibit 24: Antihypertensives – Market size and forecast 2018-2023 ($ millions)

Exhibit 25: Antihypertensives – Year-over-year growth 2019-2023 (%)

Exhibit 26: Market opportunity by product

Exhibit 27: Customer landscape

Exhibit 28: Market share by geography 2018-2023 (%)

Exhibit 29: Geographic comparison

Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: North America – Year-over-year growth 2019-2023 (%)

Exhibit 32: Top 3 countries in North America

Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in Europe

Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in Asia

Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 41: Top 3 countries in ROW

Exhibit 42: Key leading countries

Exhibit 43: Market opportunity

Exhibit 44: Impact of drivers and challenges

Exhibit 45: Vendor landscape

Exhibit 46: Landscape disruption

Exhibit 47: Vendors covered

Exhibit 48: Vendor classification

Exhibit 49: Market positioning of vendors

Exhibit 50: Amgen Inc. – Vendor overview

Exhibit 51: Amgen Inc. – Business segments

Exhibit 52: Amgen Inc. – Organizational developments

Exhibit 53: Amgen Inc. – Geographic focus

Exhibit 54: Amgen Inc. – Key offerings

Exhibit 55: Amgen Inc. – Key customer

Exhibit 56: AstraZeneca Plc – Vendor overview

Exhibit 57: AstraZeneca Plc – Business segments

Exhibit 58: AstraZeneca Plc – Organizational developments

Exhibit 59: AstraZeneca Plc – Geographic focus

Exhibit 60: AstraZeneca Plc – Key offerings

Exhibit 61: AstraZeneca Plc – Key customers

Exhibit 62: Boehringer Ingelheim International GmbH – Vendor overview

Exhibit 63: Boehringer Ingelheim International GmbH – Business segments

Exhibit 64: Boehringer Ingelheim International GmbH – Organizational developments

Exhibit 65: Boehringer Ingelheim International GmbH – Geographic focus

Exhibit 66: Boehringer Ingelheim International GmbH – Segment focus

Exhibit 67: Boehringer Ingelheim International GmbH – Key offerings

Exhibit 68: Boehringer Ingelheim International GmbH – Key customers

Exhibit 69: Bristol-Myers Squibb Co. – Vendor overview

Exhibit 70: Bristol-Myers Squibb Co. – Business segments

Exhibit 71: Bristol-Myers Squibb Co. – Organizational developments

Exhibit 72: Bristol-Myers Squibb Co. – Geographic focus

Exhibit 73: Bristol-Myers Squibb Co. – Key offerings

Exhibit 74: Bristol-Myers Squibb Co. – Key customers

Exhibit 75: Eli Lilly and Co. – Vendor overview

Exhibit 76: Eli Lilly and Co. – Business segments

Exhibit 77: Eli Lilly and Co. – Organizational developments

Exhibit 78: Eli Lilly and Co. – Geographic focus

Exhibit 79: Eli Lilly and Co. – Segment focus

Exhibit 80: Eli Lilly and Co. – Key offerings

Exhibit 81: Eli Lilly and Co. – Key customers

Exhibit 82: F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 83: F. Hoffmann-La Roche Ltd. – Business segments

Exhibit 84: F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 85: F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 86: F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 87: F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 88: F. Hoffmann-La Roche Ltd. – Key customers

Exhibit 89: Johnson & Johnson Services, Inc. – Vendor overview

Exhibit 90: Johnson & Johnson Services, Inc. – Business segments

Exhibit 91: Johnson & Johnson Services, Inc. – Organizational developments

Exhibit 92: Johnson & Johnson Services, Inc. – Geographic focus

Exhibit 93: Johnson & Johnson Services, Inc. – Segment focus

Exhibit 94: Johnson & Johnson Services, Inc. – Key offerings

Exhibit 95: Johnson & Johnson Services, Inc. – Key customers

Exhibit 96: Merck & Co. Inc. – Vendor overview

Exhibit 97: Merck & Co. Inc. – Business segments

Exhibit 98: Merck & Co. Inc. – Organizational developments

Exhibit 99: Merck & Co. Inc. – Geographic focus

Exhibit 100: Merck & Co. Inc. – Segment focus

Exhibit 101: Merck & Co. Inc. – Key offerings

Exhibit 102: Merck & Co. Inc. – Key customers

Exhibit 103: Pfizer Inc. – Vendor overview

Exhibit 104: Pfizer Inc. – Business segments

Exhibit 105: Pfizer Inc. – Organizational developments

Exhibit 106: Pfizer Inc. – Geographic focus

Exhibit 107: Pfizer Inc. – Segment focus

Exhibit 108: Pfizer Inc. – Key offerings

Exhibit 109: Pfizer Inc. – Key customers

Exhibit 110: Sanofi – Vendor overview

Exhibit 111: Sanofi – Business segments

Exhibit 112: Sanofi – Organizational developments

Exhibit 113: Sanofi – Geographic focus

Exhibit 114: Sanofi – Segment focus

Exhibit 115: Sanofi – Key offerings

Exhibit 116: Sanofi – Key customers

Exhibit 117: Validation techniques employed for market sizing

Exhibit 118: Definition of market positioning of vendors




※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様